Centrifuge to enable scalability launched through Thermo Fisher partnership

By Maggie Lynch

- Last updated on GMT

(Image: Getty/kritchanut)
(Image: Getty/kritchanut)

Related tags Thermo fisher Manufacturing Gene therapy Cell therapy Cell therapy manufacturing

Thermo Fisher and Scinogy partner to improve scalability and cost-effectiveness of cell and gene therapy manufacture through the addition of the former’s centrifuge.

Scinogy, an automated manufacturing systems provider for cell therapies, and Thermo Fisher Scientific will work to develop and commercialize reagent systems to improve the scalability of cell and gene therapy manufacturing.

With Scinogy, Thermo Fisher will provide closed, modular, and automated systems for the development and manufacturing of cell and gene therapy – to be used as an alternative method to the manual processes used in development and clinical trial supply.

Per the partnership agreement, Thermo Fisher will launch its counterflow centrifuge used for closed cell processing in cell and gene therapy manufacturing. According to the company, the Gibco CTS Rotea Counterflow Centrifugation System, is a highly reproducible system for separation, washing, and concentration of autologous and small-scale allogeneic cell therapy samples.

According to Bryan Poltilove, general manager of cell therapy for Thermo Fisher Scientific, this fulfills the market’s need for closed, modular, automated systems, which enable scalable and cost-effective development and manufacturing.

The Rotea can continuously process up to 20L of starting volume to then deliver a concentrate as small as 5ml that contains up to 200m cells per millimeter.

Politilove explained, “This centrifuge provides rapid processing of cells across a wide range of volumes with high levels of precision. By enabling closed manufacturing of cell therapies, it can reduce costs and improve scalability for commercial manufacturing.”

Financial details of the agreement have not been disclosed.

Related news

Show more

Related products

show more

Trends in Biopharmaceutical Raw Material Selection

Trends in Biopharmaceutical Raw Material Selection

Actylis – The Partner of Choice | 31-Jan-2023 | Business Advice

Join us as our in-house experts, along with Cecile Bellamy from Pfizer, discuss current and future trends in biopharmaceutical raw material selection.

Liposomal and Nanoparticle Technology

Liposomal and Nanoparticle Technology

Pfizer CentreOne | 18-Nov-2022 | Technical / White Paper

Medical science is continuously searching for better ways to administer drugs into the body and to maximize the therapeutic effectiveness of the drugs...

Connectivity & Integration in Biomanufacturing

Connectivity & Integration in Biomanufacturing

Wheeler Bio | 17-Nov-2022 | Technical / White Paper

As the Pharma 4.0 initiative sets a new industry paradigm, more biomanufacturing companies are asking how they can design and build facilities that apply...

Scalability, Quality, and Speed with Transposons

Scalability, Quality, and Speed with Transposons

Wheeler Bio | 20-Oct-2022 | Technical / White Paper

To solve for the significant bottlenecks often presented by conventional cell line development processes, this article discusses how Wheeler Bio is leveraging...

Related suppliers

Follow us


View more